-
Endo Pharma Receives CRL - Analyst Blog
Monday, January 10, 2011 - 1:02pm | 385Endo Pharmaceuticals' (ENDP) pipeline received a setback when the US Food and Drug Administration (FDA) issued a complete response letter (CRL) to the company regarding the new formulation of Opana ER. The painkiller is designed to resist attempts of crushing, breaking, pulverizing or making a...
-
AMAG 2011 Guidance Disappoints, J.P. Morgan Reports
Monday, January 10, 2011 - 11:33am | 97AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) has provided an update and pre-announces 4Q10 Feraheme revenues of $14.5- 15.5M inline with expectations, J.P. Morgan reports. “The company also provided 2011 Feraheme revenue guidance of $55-60M, which was somewhat disappointing (cons: $74M and JPMe: $94M...
-
Morning Market Movers (GENE, ACAD, PSTI, PLA)
Monday, January 10, 2011 - 11:09am | 133Genetic Technologies Ltd (NASDAQ: GENE) jumped 76.35% to $2.61 at 10:05 am. GENE had $3.29 million in total cash and $381.05 thousand in total debt for the latest quarter. ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) climbed 39.13% to $1.60. ACAD entered into a securities purchase agreement for $15...
-
Waters New Biopharmaceutical System Solution Uniquely Unites UPLC/MS Analyses and Workflows
Monday, January 10, 2011 - 10:07am | 79Waters Corporation (NYSE: WAT) today introduced its Waters Biopharmaceutical System Solution at WCBP, the 15th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products in Washington, D.C. The new Biopharmaceutical System brings together UPLC/MS...
-
Thermo Fisher Scientific Reports HSR Clearance to Acquire Dionex
Monday, January 10, 2011 - 10:02am | 50Thermo Fisher Scientific Inc. (NYSE: TMO) today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its offer to acquire Dionex (NASDAQ: DNEX).
-
Goldman Sachs Downgrading PRXL To Neutral
Monday, January 10, 2011 - 8:52am | 116Goldman Sachs is downgrading PAREXEL International (NASDAQ: PRXL) to Neutral as it is nearing its 6-m price target. “We also believe that in order for shares to move higher from here, investors will need to see better P&L performance from the company, which we do not expect will materialize...
-
Oppenheimer Maintains ENDP Rating, Estimates And PT
Monday, January 10, 2011 - 8:48am | 138On 1/7, Endo Pharmaceuticals Holdings (NASDAQ: ENDP) announced that the FDA issued a complete response letter (CRL) for the tamper resistant formulation of Opana ER, Oppenheimer reports. “We anticipate ENDP will respond to the CRL by mid-2011, with possible approval by 2012, given a six month...
-
UBS Upgrades BRKR To Buy
Monday, January 10, 2011 - 7:56am | 50Analysts at UBS upgrade Bruker Corporation (NASDAQ: BRKR) from “neutral” to “buy.” The target price for BRKR has been raised from $17 to $21. BRKR shares fell 1.23% to close at $16.00 on Friday. More Analyst Ratings here
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 5:03pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 5:03pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...
-
Shawn P. Cavanagh Appointed Cambrex COO
Friday, January 7, 2011 - 2:40pm | 40Cambrex Corporation (NYSE: CBM) announced today that, effective January 17, Shawn Cavanagh will join the Company as Executive Vice President and Chief Operating Officer, reporting to Steve Klosk, President and Chief Executive Officer.
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 2:33pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 2:09pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 2:09pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...
-
Focus Turns To Biotech Next Week - Analyst Blog
Friday, January 7, 2011 - 2:09pm | 606Zacks Small Cap Research Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference...